Who we are
The From Testing to Targeted Treatment Program (FT3), established in 2020, is an independent, nonprofit global consortium of individual patients, patient organizations, pharmaceutical & diagnostics companies, healthcare professionals and medical societies, payers, HTA bodies and regulators.
A patient-led global initiative:
8 Founding Members from patient community
Min. 40% patient representation on the Board
3 working groups co-led by patients
Quotes from members
I believe that this is the first and only global coalition to address this issue by bringing patients, advocates, pharma and diagnostic companies, HCPs, payers, and regulators who will all work together to establish best practices to make personalized care accessible to all people.